Qbrexza (glycopyrronium) is an anticholinergic medication used to treat excessive underarm sweating, also known as primary axillary hyperhidrosis, in people 9 years and older. It's available as a cloth that you use once a day to wipe both of your underarms. Common side effects include dry mouth, blurry vision, and constipation. The medication is only available under brand name Qbrexza, as a generic version isn't available.
Excessive underarm sweating (primary axillary hyperhidrosis)
Qbrexza (glycopyrronium) is an anticholinergic medication. Anticholinergics work by blocking the activity of acetylcholine, a natural chemical in the body that activates sweat glands. So applying Qbrexza (glycopyrronium) to your underarms prevents acetylcholine from working in that area, which reduces sweating.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report to your care team if they continue or are bothersome):
Is a first-choice option to treat excessive underarm sweating
Applied to the underarms, directly targeting the sweat glands
Only need to apply once a day, every 24 hours
Can cause problems urinating and blurred vision
Interacts with other anticholinergic medications
Risk of accidental exposure to others, especially children, leading to unwanted side effects
Qbrexza (glycopyrronium) is only FDA approved to treat excessive underarm sweating. Don’t use this medication on other parts of your body, unless directed by your prescriber.
Make sure to wipe Qbrexza (glycopyrronium) across clean dry skin. Don’t apply Qbrexza (glycopyrronium) if you have any cuts or tears on your underarms. Doing so can affect how well the drug works for you.
Wash your hands after using Qbrexza (glycopyrronium) to prevent your body from absorbing any extra medication. If you don't wash your hands and accidentally touch your eyes, you could experience blurry vision.
Throw away the used Qbrexza (glycopyrronium) wipe in the trash out of reach of others, especially children. There have been reports of children experiencing blurry vision and other eye problems after touching their eyes following contact with the used wipe.
Don’t drive or participate in activities requiring you to be alert if you have blurry vision while taking Qbrexza (glycopyrronium). You should stop taking this medication and contact a prescriber as soon as you notice these symptoms.
Dry mouth is a common side effect with Qbrexza (glycopyrronium). If this becomes bothersome, you can try remedies at home like chewing sugar-free gum, sipping cold water throughout the day, and using over-the-counter saliva substitutes to help.
Qbrexza (glycopyrronium) is an anticholinergic medication, and taking it with other anticholinergic medications can raise your risk for specific side effects like dry mouth, blurry vision, and constipation. When starting a new medication, check with a prescriber or pharmacist to make sure it doesn’t interact with Qbrexza (glycopyrronium).
Qbrexza (glycopyrronium) is a flammable medication, meaning it can easily catch on fire. Store it at room temperature in a cool, dry area, away from heat and flame.
Qbrexza (glycopyrronium) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Risk factors: Enlarged Prostate | Blockage in the bladder
As with other anticholinergic medications, Qbrexza (glycopyrronium) can cause difficulty urinating. If you’ve had trouble emptying your bladder in the past, this medication can worsen your condition. Stop this medication right away if you have any difficulty passing urine, and contact your prescriber when you first notice these symptoms.
Risk factors: Taking another anticholinergic medication | Exposed to hot or warm environments
People taking Qbrexza (glycopyrronium) are at a higher risk for heat strokes and high body temperatures when exposed to hot environments. Normally, sweating helps cool your body down in high temperatures, but Qbrexza (glycopyrronium) reduces sweating, raising the risk of overheating and heat stroke. If you notice you're sweating less, have red hot skin, fever, dizziness, or difficulty breathing, stop using the medication and contact your prescriber right away.
Risk factors: Taking another anticholinergic medication
You might temporarily have trouble seeing while taking Qbrexza (glycopyrronium), but it usually doesn't last long. If this happens, avoid driving, operating machinery, or doing anything that requires clear vision. Stop taking the medication until your vision improves, and contact your prescriber as soon as you notice blurry vision.
Dosage | Quantity | Price as low as | Price per unit |
---|---|---|---|
2.8g of 2.4% | 1 box | $570.18 | $570.18 |
Wipe one cloth across one entire underarm once. Then, use the same cloth to wipe the other underarm once. Repeat these steps once a day, every 24 hours.
Stomach or intestinal blockage
Unstable heart health during severe bleeding
Severe ulcerative colitis
Excessive underarm sweating (primary axillary hyperhidrosis)
Overactive bladder (OAB) in adults
Loss of bladder control due to nerve problems in people 5 years and older
Headache prevention in adults with long-term migraine (headaches lasting 4 hours or longer for 15 or more days per month)
Muscle spasms in people 2 years and older
Neck spasms in adults
Excessive armpit sweating in adults
Eyelid twitching in people 12 years and older
Crossed eyes in people 12 years and older
Excessive sweating (hyperhidrosis)
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
Glaser, D. A., et al. (2019). A 44-week open-label study evaluating safety and efficacy of topical glycopyrronium tosylate in patients with primary axillary hyperhidrosis. American Journal of Clinical Dermatology.
Hu, Y., et al. (2018). Neural control of sweat secretion: A review. The British Journal of Dermatology.
Hyun, M. Y., et al. (2014). Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: A randomized, multicentre, double-blinded, placebo-controlled, split-face study. Journal of the European Academy of Dermatology & Venereology.
International Hyperhidrosis Society. (n.d.). Primary focal axillary hyperhidrosis.
Journey Medical Corporation. (2023). Qbrexza- glycopyrronium cloth [package insert]. DailyMed.
Ludmann, P. (2024). Hyperhidrosis: Diagnosis and treatment. American Academy of Dermatology Association.
Pariser, D., et al. (2022). Open-label cohort study to evaluate efficacy and safety of application of glycopyrronium cloth, 2.4% for palmar hyperhidrosis. Journal of Drugs in Dermatology.
Pariser, D. M., et al. (2019). Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Patient-reported outcomes from the ATMOS-1 and ATMOS-2 phase III randomized controlled trials. American Journal of Clinical Dermatology.
Pariser, D. M., et al. (2021). Limited systemic exposure with topical glycopyrronium tosylate in primary axillary hyperhidrosis. Clinical Pharmacokinetics.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.